Imaging: Prostate Cancer VL

PRINCE Trial Highlights Early Detection of Prostate Cancer Progression with PSMA PET-CT - Michael Hofman

Details
Michael Hofman discusses the development of new criteria for evaluating prostate cancer progression using PSMA PET-CT scans. This work aims to standardize response evaluation and potentially replace the current PCWG3 guidelines that rely on CT and bone scans. Using data from the PRINCE trial, Dr. Hofman's team demonstrates high inter-reader agreement for the new criteria, with almost perfect agree...

Phase 3 CLARIFY Trial Investigates 64Cu-SAR-bisPSMA PET for Improved Prostate Cancer Detection - Louise Emmett

Details
Louise Emmett discusses the novel copper-64 bisPSMA agent for prostate cancer imaging. She explains its unique features, including a 12-hour half-life and bifid peptide structure, which potentially offer improved imaging characteristics over existing PSMA agents. Dr. Emmett highlights early study results showing higher intensity uptake in cancer cells compared to gallium PSMA-11. The conversation...

CLARIFY Trial: Advancing Prostate Cancer Imaging with 64Cu-SAR-bisPSMA PET - Neal Shore

Details
Neal Shore discusses a new 64Cu-SAR-bisPSMA PET diagnostic agent for prostate cancer imaging with Phillip Koo. Dr. Shore highlights the unique features of this compound, including its bivalent structure and longer half-life compared to existing PSMA PET agents. He explains how these characteristics allow for next-day imaging, potentially improving detection rates and clinical flexibility. Dr. Shor...

PSMA PET in Prostate Cancer: Balancing Sensitivity and Clinical Relevance - Ravi Madan

Details
Oliver Sartor discusses with Ravi Madan the implications of using PSMA PET scans in metastatic castration-resistant prostate cancer. Dr. Madan highlights concerns about prematurely changing treatments based on PSMA PET findings without established criteria for progression. He emphasizes the distinction between radiological progression and treatment failure, noting the lack of validated parameters...

COBRA Trial: Evaluating 64Cu-SAR-bisPSMA PET Imaging for Prostate Cancer Detection - Phillip Koo

Details
Zachary Klaassen and Phillip Koo discuss the results from the COBRA study, focusing on the innovative 64Cu-SAR-bisPSMA PET imaging presented at ASCO 2024. Dr. Koo explains that this new imaging agent has unique dual binding sites and advanced chelator technology, enhancing its attachment to prostate cancer cells and increasing the detection rate. The COBRA trial reveals that imaging performed the...

Comparing PSMA Ligands for Prostate Cancer Imaging - Michael Hofman

Details
Alicia Morgans discusses advances in prostate cancer imaging and theranostics with Michael Hofman. Dr. Hofman emphasizes the growing variety of PSMA ligands for PET-CT imaging and treatment, comparing their subtle differences and implications for clinical practice. He notes that while ligands like Gallium PSMA-11 and DCFPyL are similar and FDA-approved, others like PSMA-1007, although widely used...

COBRA Trial Shows Promise for 64Cu-SAR-bisPSMA PET in Biochemical Recurrence - Neal Shore

Details
Phillip Koo and Neal Shore discuss the COBRA trial, which investigates the use of 64Cu-SAR-bisPSMA PET imaging in prostate cancer patients with biochemical recurrence (BCR). Dr. Shore, the lead principal investigator, introduces Clarity, an Australian company developing Copper-64-based radiopharmaceuticals. He explains the advantages of Copper-64, such as its long half-life and bivalent structure,...

INDICATE Trial Seeks to Clarify Role of PET Scans in Prostate Cancer Recurrence - Neha Vapiwala

Details
Alicia Morgans interviews Neha Vapiwala about the innovative phase three INDICATE trial, supported by the ECOG-ACRIN Group and NCI designated cooperative groups. The trial focuses on patients with biochemical recurrence after prostatectomy, examining the impact of PET scans on treatment decisions. It categorizes patients based on PET scan results: those without detectable cancer outside the pelvis...

The 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer - Faina Shtern

Details
Phillip Koo converses with Faina Shtern who highlights that this year's Summit aims to bridge the significant gaps between the imaging community and clinical community. She emphasizes the future of prostate cancer diagnosis and treatment lies in the integration of multiple diagnostic methods such as MRI, molecular imaging, and genomic profiling. The 2023 Summit will introduce a multiomics panel fo...

PSMA PET's Influence on Prostate Cancer Studies - Jeremie Calais

Details
Phillip Koo talks with Jeremie Calais about the EMBARK trial and the impact of PSMA PET on patient population characterization. The discussion explores how the EMBARK trial began back in 2015 before the existence of PSMA PET and how its introduction has affected the understanding and definition of patient populations in prostate cancer studies. Calais explains how their team retrospectively looked...